Skip to main content

rp2

Generic: sturlimgene erparepvec·Code: RP2

rp2: sourced relationships with 1 company · 5 clinical trials tracked.

rp2 evidence translation

What we can confirm

What it means

Source-backed records connect rp2 to REPL; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could rp2 → REPL affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 0 study sponsors

Related indications

Hepatocellular Carcinoma; Gastric Adenocarcinoma; CancerBiliary Tract CancerCancerHepatocellular Carcinoma

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
Replimune Group, Inc. (REPL)
developer · Reported 2026-06-29 · Current development: unknownSource
Hepatocellular Carcinoma; Gastric Adenocarcinoma; Cancer
Phase 3
Clinical Trial Registry Records (5)

Phase II Study of Neoadjuvant RP2 in Combination With Preoperative Flot for Patients With Stage II or Higher, Non-metastatic Gastroesophageal Adenocarcinoma

NCT07059611Registry updated 2026-01-12·Phase 2
Not yet recruiting

Primary endpoint: Pathologic complete response

Interventionalopen34 targetStarted 2026-04Completion 2029-111 site · United StatesAbramson Cancer Center at Penn Medicine

A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

NCT06581406Registry updated 2026-02-18·Phase 3
Recruiting

Primary endpoint: Overall Survival (OS)

InterventionalRandomizedopen280 targetStarted 2024-12Completion 2031-1031 sites · United Kingdom, United StatesReplimune Inc.

A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma

NCT05733598Registry updated 2025-12-15·Phase 2
Recruiting

Primary endpoint: Overall Response Rate per modified RECIST 1.1

Interventionalopen60 targetStarted 2024-08Completion 2028-0711 sites · United StatesReplimune Inc.

A Phase 2 Clinical Trial Investigating Oncolytic Immunotherapy in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With Advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma

NCT05733611Registry updated 2026-02-02·Phase 2
Terminated

Primary endpoint: Objective Response Rate (ORR)

Interventionalopen5 targetStarted 2023-06Completion 2025-082 sites · United StatesReplimune Inc.

An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors

NCT04336241Registry updated 2025-09-09·Phase 1
Recruiting

Primary endpoint: Percentage of adverse events (AEs)

Interventionalopen36 targetStarted 2019-10Completion 2028-047 sites · Spain, United KingdomReplimune Inc.

Frequently asked questions

Which companies have sourced relationships with rp2?

rp2 has dated SEC/FDA relationship records for Replimune Group, Inc..

How many clinical trials involve rp2?

BioSniper tracks 5 clinical trials involving rp2.